Senator Chris Van Hollen @ChrisVanHollen
Taxpayers paid nearly $71M to help develop Remdesivir. Now taxpayers will pay again with its excessive $3K+ price tag. Just another reason we must pass the We PAID Act. If taxpayers help develop the drug, companies should charge them a reasonable price. https://t.co/PSMlVw5U7D — PolitiTweet.org